Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)
- Conditions
- Coronary Arterial Disease (CAD)Percutaneous Coronary Intervention (PCI)
- Interventions
- Drug: Dual Antiplatelet (DAPT) Therapy
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- J.P.S Henriques
- Target Recruit Count
- 300
- Registration Number
- NCT06916520
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 78
- Registration Number
- NCT06821191
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 48
- Registration Number
- NCT06691191
- Locations
- 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 90
- Registration Number
- NCT05681702
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Germano Di Sciascio
- Target Recruit Count
- 50
- Registration Number
- NCT05643586
- Locations
- 🇧🇪
Aalst cardiovascular center, Aalst, Belgium
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
- Conditions
- ST Elevated Myocardial InfarctionDual Antiplatelet Therapy
- Interventions
- Device: OCT guided revascularizationDevice: Angio guided revascularization
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Research Maatschap Cardiologen Rotterdam Zuid
- Target Recruit Count
- 1608
- Registration Number
- NCT05491200
- Locations
- 🇮🇹
University Gemelli, Roma, Italy
🇳🇱Haga hospital, Den Haag, Netherlands
🇮🇹University Federico II, Napoli, Italy
Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm
- Conditions
- Intracranial Aneurysm
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 406
- Registration Number
- NCT05359224
- Locations
- 🇰🇷
Yongin Severance hospital, Yonsei university college of medicine, Gyeonggi-do, Yongin-si, Korea, Republic of
Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 87
- Registration Number
- NCT05247385
- Locations
- 🇧🇷
Heart Institute (InCor) / University of São Paulo, São Paulo, Sao Paulo, Brazil
Clopidogrel Monotherapy in Patients With High Bleeding Risk
- Conditions
- Bleeding Complications
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 98
- Registration Number
- NCT05223335
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 16000
- Registration Number
- NCT05183178
- Locations
- 🇸🇪
Dep. Cardiology, Skånes universitetssjukhus, Lund, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.